Back
Rate this talk
Your peers have not rated this talk yet.
10-minute watch | Talk 5 of 5

ICML: Evolving survival outcomes with CAR T in 2L DLBCL

CAR T in 2L DLBCL: A case study

Dr Jason Westin
SYMPOSIUM
ICML

Dr Jason Westin
MD Anderson Cancer Center, Houston, Texas, USA

Dr Jason Westin, MD Anderson Cancer Center, Houston, Texas, USA, describes 3 case studies exploring eligibility for CAR T cell therapy, highlighting the new treatment paradigm in R/R DLBCL

Read more

Talks in this series

Dr Anna Sureda, Dr Michael Dickinson, Dr Frederick Locke and Dr Jason Westin present at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
1-minute watch | Talk 1 of 5
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
Series trailer
Dr Anna Sureda, Dr Michael Dickinson, Dr Frederick Locke and Dr Jason Westin present at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
1-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL

Series trailer

Dr Anna Sureda presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
5-minute watch | Talk 2 of 5
Welcome & introduction
Dr Anna Sureda
Dr Anna Sureda presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
5-minute watch

Welcome & introduction

Dr Anna Sureda

Dr Michael Dickinson presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
9-minute watch | Talk 3 of 5
Defining the unmet need in 2L DLBCL
Dr Michael Dickinson
Dr Michael Dickinson presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
9-minute watch

Defining the unmet need in 2L DLBCL

Dr Michael Dickinson

Dr Frederick Locke presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
23-minute watch | Talk 4 of 5
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Frederick Locke, Dr Matthew Lunning
Dr Frederick Locke presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
23-minute watch

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Frederick Locke, Dr Matthew Lunning

Dr Jason Westin presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
10-minute watch | Talk 5 of 5
CAR T in 2L DLBCL: A case study
Dr Jason Westin
Dr Jason Westin presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
10-minute watch

CAR T in 2L DLBCL: A case study

Dr Jason Westin

Dr Anna Sureda, Dr Michael Dickinson, Dr Frederick Locke and Dr Jason Westin present at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
1-minute watch | Talk 1 of 5
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
Series trailer
Dr Anna Sureda, Dr Michael Dickinson, Dr Frederick Locke and Dr Jason Westin present at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
1-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL

Series trailer

Dr Anna Sureda presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
5-minute watch | Talk 2 of 5
Welcome & introduction
Dr Anna Sureda
Dr Anna Sureda presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
5-minute watch

Welcome & introduction

Dr Anna Sureda

Dr Michael Dickinson presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
9-minute watch | Talk 3 of 5
Defining the unmet need in 2L DLBCL
Dr Michael Dickinson
Dr Michael Dickinson presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
9-minute watch

Defining the unmet need in 2L DLBCL

Dr Michael Dickinson

Dr Frederick Locke presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
23-minute watch | Talk 4 of 5
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Frederick Locke, Dr Matthew Lunning
Dr Frederick Locke presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
23-minute watch

How has CAR T changed the 2L DLBCL treatment landscape?

Dr Frederick Locke, Dr Matthew Lunning

Dr Jason Westin presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
10-minute watch | Talk 5 of 5
CAR T in 2L DLBCL: A case study
Dr Jason Westin
Dr Jason Westin presents at ICML (Evolving survival outcomes with CAR T in 2L DLBCL)
10-minute watch

CAR T in 2L DLBCL: A case study

Dr Jason Westin

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.